# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: John Henry Holliday (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI007-SYN-TD
- Date: 1873-03-17
- Fictional facility: St. Posthumous Health Center
- Fictional author: Martin Beaumont, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Five-week review: susceptibility results, release from isolation, and liver monitoring. **S**

## History of present illness

Mr. Holliday returns five weeks into treatment. The isolate is susceptible to isoniazid, rifampin, pyrazinamide, and ethambutol, and ethambutol was stopped a week ago when the result arrived. The three sputum smears collected in the third week were negative, and with his clinical improvement and more than two weeks of treatment he was released from home isolation two weeks ago and returned to work the following week. His cough is now occasional and dry, and the night sweats have stopped. He has taken every dose by video. He has no nausea now, no yellowing, dark urine, abdominal pain, numbness, or vision change. He has not had a drink in three weeks and has met his counselor twice. His roommate's first blood test was negative and will be repeated by the health department. **S**

| Element | Detail |
|---|---|
| Susceptibility | Susceptible to all four first-line drugs; ethambutol stopped a week ago |
| Infection control | Three negative smears; released from isolation and back at work |
| Symptoms | Occasional dry cough; no night sweats |
| Alcohol | None for three weeks; two counseling sessions |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Occasional dry cough; no sputum or blood |
| Constitutional | Negative | No fever or night sweats; appetite good |
| Gastrointestinal | Negative | No nausea, abdominal pain, or jaundice |
| Psychiatric | Negative | Mood better since returning to work; no thoughts of suicide or self-harm |

4 systems reviewed. **S**

## Current medications

- Isoniazid 300 mg tablet, one tablet daily **S**
- Rifampin 300 mg capsules, two capsules (600 mg) daily **S**
- Pyrazinamide 500 mg tablets, three tablets (1500 mg) daily **S**
- Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 116/72 mmHg; pulse 84 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 97% on room air; weight 61 kg; BMI 19.3 kg/m². All vital signs are synthetic.

ALT: 52 U/L; AST: 47 U/L (high); Total bilirubin: 0.8 mg/dL; AUDIT-C: 2. All results are synthetic.

## Change since baseline

- ALT: 34 U/L at baseline, 52 U/L at this visit **S**
- AST: 38 U/L at baseline, 47 U/L (high) at this visit **S**
- Total bilirubin: 0.6 mg/dL at baseline, 0.8 mg/dL at this visit **S**
- AUDIT-C: 9 at baseline, 2 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 61.0 kg; temperature 36.8 °C |
| Eyes | No icterus |
| Respiratory | A few crackles at the right apex; no bronchial breathing |
| Abdomen | Soft; liver not enlarged or tender |
| Neurological | Normal sensation in the feet |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Drug-susceptible pulmonary tuberculosis, intensive phase** (A15.0). Good response, with sputum smear conversion. AST 47 U/L is slightly above the upper limit, with ALT 52 and bilirubin 0.8 normal and no symptoms; this is well below the threshold for drug-induced liver injury. **S**
   - Continue isoniazid, rifampin, pyrazinamide, and pyridoxine daily by video; ethambutol stays stopped.
   - Liver tests again at the two-month visit.
   - Sputum culture again at the two-month visit, which decides whether the continuation phase lasts four or seven months.
2. **Alcohol use disorder, mild** (F10.10). No alcohol for three weeks; AUDIT-C 2 for the past month. Safety reviewed: no thoughts of suicide. **S**
   - Continue counseling every two weeks.
   - Keep to no alcohol while the liver is under strain from three drugs.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptom review: cough, sputum, hemoptysis, fever, night sweats | At least monthly during treatment | Completed today | Occasional dry cough only |
| Examination | Weight | At least monthly during treatment | Completed today | 61.0 kg, up 3.0 kg since diagnosis |
| Medication safety | Hepatitis symptom review (nausea, vomiting, abdominal pain, jaundice, dark urine) | Every visit and every observed dose | Completed today | None |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Baseline, at two weeks, then monthly because of alcohol use | Completed today | ALT 52 U/L normal, AST 47 U/L slightly high, bilirubin 0.8 mg/dL normal; no symptoms |
| Imaging | Visual acuity and color vision | Baseline and monthly while on ethambutol | Not indicated | Ethambutol stopped a week ago, after normal checks at baseline and two weeks |
| Laboratory | Drug susceptibility testing of the first isolate | Once, on the first positive culture | Completed today | Susceptible to isoniazid, rifampin, pyrazinamide, and ethambutol |
| Laboratory | Sputum AFB smear and culture | Monthly until two consecutive cultures are negative | Completed today | Three smears in the third week negative; cultures from those samples pending |
| Medication safety | Doses observed and missed (video-observed therapy) | Every visit | Completed today | All doses observed |
| Medication safety | Peripheral neuropathy check, with pyridoxine | Every visit | Completed today | No neuropathy |
| Self-management | Home isolation and the criteria for release | Until three negative smears, clinical improvement, and two weeks of treatment | Completed today | Release criteria met two weeks ago; back at work, with the health department's agreement |
| Referral | Contact investigation (household, coworkers, patients) | Led by the health department, from diagnosis | Referred | In progress with the health department |
| Survey | Alcohol use (AUDIT-C for the past month) | Every visit | Completed today | AUDIT-C 2 for the past month; none in three weeks |
| Self-management | Brief counseling about alcohol and liver risk | Every visit | Completed today | Goal of no alcohol reinforced |
| Referral | Counseling with a substance-use counselor | Every one to two weeks during treatment | Completed today | Two sessions so far |
| Medication safety | Medication for alcohol use disorder | Offered for alcohol use disorder | Not indicated | Not wanted; doing well with counseling |
| Survey | Suicide-risk review and safety plan, with the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide |

## Goal progress

- Complete 182 doses of treatment under video-observed therapy within six months. In progress; target 1873-08-18. **S**
- Sputum culture negative at two months. In progress; target 1873-08-18. **S**
- No alcohol during treatment, to protect his liver. In progress; target 1873-08-18. **S**
- Return to work once he is no longer infectious. Outcome by 1873-03-17: Released from home isolation after three negative sputum smears and back at work four weeks into treatment. **S**
- Weight back to at least 64 kg by the end of treatment. In progress; target 1873-08-18. **S**

## Guideline basis

- Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016), American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America (Clinical Infectious Diseases)
- An official ATS statement: hepatotoxicity of antituberculosis therapy (2006), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine)
- Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense

## Follow-up

- Two-month review with sputum culture and liver tests. **S**
- Next scheduled visit 1873-04-14: end of the intensive phase: two-month sputum and the start of the continuation phase. **S**
